Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAndrographolideAndrographol.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

    
  
Andrographolide for COVID-19
7 studies from 62 scientists
1,245 patients in 2 countries
Statistically significant lower risk for recovery.
2 studies from 2 independent teams in 2 countries show significant improvements.
COVID-19 Andrographolide studies. Jul 2024. c19early.org
0 0.5 1 1.5+ All studies 27% Hospitalization 50% Recovery 30% Viral clearance 28% RCTs 41% Early 40% Late 10% Favorsandrographolide Favorscontrol
Jul 20
Covid Analysis Andrographolide for COVID-19: real-time meta analysis of 7 studies
Statistically significant lower risk is seen for recovery. 2 studies from 2 independent teams in 2 countries show significant improvements. Meta analysis using the most serious outcome reported shows 27% [-8‑50%] lower risk, wi..
Jul 1
Chaopreecha et al., Elsevier BV, doi:10.2139/ssrn.4876852 Proteomic Analysis Identifies the Glutathione Synthesizing Enzyme Gclc as an Andrographolide Target and a Protective Factor Against Sars-Cov-2 Infection
In Vitro study showing andrographolide attenuates infection of SARS-CoV-2 wildtype and omicron variants in human lung epithelial cells and monkey kidney cells. Proteomic analysis revealed andrographolide induces expression of the glutathi..
Jun 14
Li et al., Antiviral Therapy, doi:10.1177/13596535241259952 Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study
In Vitro study showing that andrographolide downregulates ACE2 expression and inhibits SARS-CoV-2 pseudovirus infection in a dose-dependent manner in human cells. Authors constructed a screening platform with a dual-luciferase reporter ve..
Apr 29
Thomas et al., Scientific Reports, doi:10.1038/s41598-024-58532-7 Cheminformatics approach to identify andrographolide derivatives as dual inhibitors of methyltransferases (nsp14 and nsp16) of SARS-CoV-2
In Silico study showing that andrographolide derivatives (PubChem CID 2734589 and 138968421) are potential dual inhibitors of SARS-CoV-2 methyltransferases nsp14 and nsp16, which are crucial for viral replication and evading host immune r..
Feb 22
Low et al., bioRxiv, doi:10.1101/2024.02.21.581396 The wide spectrum anti-inflammatory activity of andrographolide in comparison to NSAIDs: a promising therapeutic compound against the cytokine storm
In vitro study showing that andrographolide exhibits broad anti-inflammatory and cytokine inhibiting activity against lipopolysaccharide (LPS) and interferon-γ induced inflammation in murine RAW264.7 and human THP-1 macrophage cell lines...
Feb 21
Wan et al., Scientific Reports, doi:10.1038/s41598-024-54722-5 Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level
In Vitro and mouse study showing that andrographolide and baicalin have synergistic antiviral effects against SARS-CoV-2. Andrographolide and baicalin inhibited binding between the SARS-CoV-2 spike protein and ACE2 receptor in human cells..
Feb 2
Prasoppokakorn et al., OBM Integrative and Complementary Medicine, doi:10.21926/obm.icm.2401013 Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial
37% improved recovery (p=0.005). Randomized controlled trial of 82 mild COVID-19 outpatients showing significantly greater reduction in cough and lower inflammatory markers at day 7. Symptomatic improvement was significant at day 7 when combining all symptoms reported, b..
Dec 21
2023
Yarnvitayalert et al., 2023 IEEE 5th Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability, doi:10.3390/engproc2023055081 Dynamic Model of Andrographolide Therapy for COVID-19
Pharmacokinetic and pharmacodynamic modeling of andrographolide for COVID-19. The model suggests that a dose of 60mg per day of andrographolide is optimal for reducing viral load and infection. The model incorporates the diffusion of the ..
Dec 7
2023
Wijewickrama et al., Journal of Ethnopharmacology, doi:10.1016/j.jep.2023.117535 Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial
RCT 171 hospitalized COVID-19 patients in Sri Lanka, showing improved viral clearance and recovery, without statistical significance, for treatment with Link Natural Sudarshana (LNS). LNS is an Ayurvedic herbal preparation containing 49 m..
Nov 23
2023
Kanokkangsadal et al., Research in Pharmaceutical Sciences, doi:10.4103/1735-5362.389947 Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial
51% lower progression (p=0.25) and 8% improved recovery (p=0.33). RCT 165 low-risk mild COVID-19 patients in Thailand receiving either 180mg/day of Andrographis paniculata extract or placebo for 5 days. No significant difference was found between groups for disease progression, though A. paniculata show..
Nov 15
2023
Bhardwaj et al., Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2023.100778 Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial
13% shorter hospitalization (p=0.05) and 12% faster viral clearance (p=0.02). RCT 150 mild-moderate COVID-19 patients showing faster viral clearance and shorter hospitalization with NAOQ19, a polyherbal formulation containing 13 antiviral/antinflammatory compounds. NAOQ19 ingredients include curcumin, andrographis,..
Nov 13
2023
Siridechakorn et al., Scientific Reports, doi:10.1038/s41598-023-46249-y Inhibitory efficiency of Andrographis paniculata extract on viral multiplication and nitric oxide production
In Vitro study analyzing the antiviral and anti-inflammatory properties of extracts and fractions from Andrographis paniculata, against herpes simplex virus-1 (HSV-1) and influenza A virus H3N2 as surrogates for COVID-19. The results show..
Sep 16
2023
Mohd Abd Razak et al., Natural Product Communications, doi:10.1177/1934578X231188861 In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds
In vitro study showing that of 9 phenolic compounds tested, only curcumin inhibited SARS-CoV-2 cytopathic effects in infected monkey kidney Vero E6 cells. Curcumin showed antiviral activity against wildtype, alpha, delta, and omicron vari..
Aug 22
2023
Ratiani et al., Pharmaceuticals, doi:10.3390/ph16091196 Efficacy of Kan Jang® in Patients with Mild COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial
71% lower progression (p=0.03), 70% improved recovery (p=0.07), and 41% faster viral clearance (p=0.12). RCT 140 mild COVID-19 patients treated within 3 days of onset, showing lower progression and improved recovery with Kan Jang (andrographis + eleuthero).
Aug 12
2023
Siripongboonsitti et al., Phytomedicine, doi:10.1016/j.phymed.2023.155018 Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
86% lower need for oxygen therapy (p=0.24), 37% improved recovery (p=0.28), and 5% worse viral clearance (p=0.46). RCT 146 mild/moderate COVID-19 patients in Thailand, showing no significant difference in clinical outcomes. There were very few serious outcomes.
Jun 30
2023
Pu et al., Phytomedicine, doi:10.1016/j.phymed.2023.154753 The effects and mechanisms of the anti-COVID-19 traditional Chinese medicine, Dehydroandrographolide from Andrographis paniculata (Burm.f.) Wall, on acute lung injury by the inhibition of NLRP3-mediated pyroptosis
In Vitro and mouse study investigating the potential therapeutic effects of dehydroandrographolide (Deh), a compound from the herb Andrographis paniculata, in models of acute lung injury caused by COVID-19 infection. Deh reduced inflammat..
May 31
2023
Benjaponpitak et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0146 Effect of Andrographis paniculata Treatment for Nonimmune Patients with Early-Stage COVID-19 on the Prevention of Pneumonia: A Retrospective Cohort Study
98% lower progression (p<0.0001). Retrospective 528 asymptomatic/mild patients in Thailand, showing lower progression to pneumonia with andrographis treatment.
Feb 28
2023
Shanker et al., Phytomedicine Plus, doi:10.1016/j.phyplu.2022.100398 A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19
91% lower progression (p=0.05), 33% faster recovery (p<0.0001), and 6% improved viral clearance (p=1). 80 mild/moderate hospitalized COVID-19 patients in India, 40 treated with CIM-MEG19 (standardized Andrographis paniculata formulation), showing faster recovery, lower progression, and favorable changes in inflammatory markers, however the..
Feb 21
2023
Savaliya et al., AYU (An International Quarterly Journal of Research in Ayurveda), doi:10.4103/ayu.ayu_92_22 Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial
86% improved recovery (p<0.0001) and 53% improved viral clearance (p<0.0001). RCT with 300 mild to moderate hospitalized COVID-19 patients, showing faster recovery, faster viral clearance, and a reduction in inflammatory markers with COROPROTECT, which includes curcumin, andrographis, and several additional treatme..
Jan 12
2023
Nguyen et al., Bioinformatics and Biology Insights, doi:10.1177/11779322221149622 The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics
In Silico study identifying multiple compounds including andrographolide, quercetin, and hydroxychloroquine (used as a reference) as promising inhibitors of SARS-CoV-2. Authors note the potential synergistic effect of multiple compounds.
Dec 31
2022
Prempree et al., OSIR, 15:4 SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study
19% improved viral clearance (p=0.61). Retrospective 120 patients in Thailand, showing improved viral clearance with andrographis compared with favipiravir.
Sep 22
2022
Dassanayake et al., International Journal of Molecular Sciences, doi:10.3390/ijms231911131 Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus
In Silico study showing that the phytochemical andrographolide derived from Andrographis paniculata binds strongly to the spike proteins of six SARS-CoV-2 variants, including the B.1.1.7 UK, B.1.351 South African, P.1 Japan/Brazil, B.1.42..
Aug 10
2022
Tanwettiyanont et al., Frontiers in Medicine, doi:10.3389/fmed.2022.947373 Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study
26% higher progression (p=0.4). Retrospective 605 hospitalized patients in Thailand, showing higher progression with andrographis, without statistical significance.
Jul 13
2022
Intharuksa et al., Molecules, doi:10.3390/molecules27144479 A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery
Review of Andrographis paniculata extracts and compounds like andrographolide with antiviral, anti-inflammatory, and immunomodulatory properties that could help treat COVID-19 symptoms and progression. In silico studies suggest these comp..
Jun 30
2022
Ningrum et al., Proceedings Universitas Muhammadiyah Yogyakarta Undergraduate Conference, doi:10.18196/umygrace.v2i2.418 Potency Of Andrographolide, L-Mimosine And Asiaticoside Compound As Antiviral For Covid-19 Based On In Silico Method
In Silico study showing that andrographolide, L-mimosine, and asiaticoside compounds from Andrographis paniculata, Mimosa pudica and Centella asiatica plants have potential as COVID-19 antivirals by binding to SARS-CoV-2 3CLpro, NSP3, and..
May 30
2022
Numthavaj et al., NCT05178173 Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19
Estimated 3,060 patient andrographolide early treatment RCT with results not reported over 2 years after estimated completion.
Mar 28
2022
Ravichandran et al., Biointerface Research in Applied Chemistry, doi:10.33263/BRIAC132.155 Identification of Potential Semisynthetic Andrographolide Derivatives to Combat COVID-19 by Targeting the SARS-COV-2 Spike Protein and Human ACE2 Receptor– An In-silico Approach
In Silico study showing that semisynthetic andrographolide derivatives have potential to inhibit SARS-CoV-2 infection by targeting the spike protein and human ACE2 receptor. Docking studies found that derivatives AGP15 and AGP14 had the h..
Jan 31
2022
Saeheng et al., The American Journal of Chinese Medicine, doi:10.1142/S0192415X22500732 In Silico Prediction of Andrographolide Dosage Regimens for COVID-19 Treatment
In Silico study showing potential benefits of andrographolide for COVID-19 treatment and optimal dosage regimens predicted by physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling. Authors find that oral crude extra..
Dec 31
2021
Khanal et al., RSC Advances, doi:10.1039/D0RA10529E Combination of system biology to probe the anti-viral activity of andrographolide and its derivative against COVID-19
In Silico study showing that andrographolide and 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata modulate immune pathways and bind to SARS-CoV-2 papain-like protease, main protease, and spike protein. Authors find tha..
Dec 27
2021
Bhardwaja et al., Research Square, doi:10.21203/rs.3.rs-1165680/v1 An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial
89% improved recovery (p=0.05) and 24% improved viral clearance (p=0.47). Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin, andrographis, and antiandrogen glycyrrhiza glabra.
Jul 11
2021
Wanaratna et al., Archives of Internal Medicine Research, doi:10.26502/aimr.0125 (date from preprint) Efficacy and Safety of Andrographis Paniculata Extract in Patients with Mild COVID-19: A Randomized Controlled Trial
86% lower progression (p=0.11) and 40% improved viral clearance (p=0.11). RCT 63 mild COVID-19 patients showing lower progression and improved viral clearance with andrographis, without statistical significance.
Jun 24
2021
Rehan et al., Frontiers in Immunology, doi:10.3389/fimmu.2021.648250 A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm
In Silico study showing that andrographolide, a compound from Andrographis paniculata, may reduce cytokine storm in COVID-19 by targeting the TNF signaling pathway. Authors found that andrographolide binds to TNF and NFkB1 proteins, poten..
May 12
2021
Zhang et al., Phytotherapy Research, doi:10.1002/ptr.7141 Efficacy and safety of Xiyanping injection in the treatment of COVID‐19: A multicenter, prospective, open‐label and randomized controlled trial
92% lower severe cases (p=0.03), 48% improved recovery (p=0.008), and 53% improved viral clearance (p=0.0001). RCT 130 hospitalized COVID-19 patients in China, showing lower progression and improved recovery with Xiyanping injection (9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate, which are derived f..
Oct 16
2020
Rajagopal et al., Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach
In Silico study of several phytochemical compounds from Curcuma longa (turmeric) and Andrographis paniculata for their potential activity against COVID-19 by targeting the SARS-CoV-2 main protease. Molecular docking analysis found the tur..
Jun 18
2020
Dey et al., Research Square, doi:10.21203/rs.3.rs-35800/v1 The role of andrographolide and its derivative in COVID-19 associated proteins and immune system
In Silico study showing that andrographolide and its derivative 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata may be beneficial for COVID-19 by binding to key SARS-CoV-2 proteins and modulating immune pathways. Auth..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit